Juno Therapeutics (JUNO) saw its loss widen to $56.90 million, or $0.56 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $23.24 million, or $0.26 a share. On the other hand, adjusted net loss for the quarter widened to $58.27 million, or $0.57 a share from a loss of $46.27 million or $0.52 a share, a year ago.
Revenue during the quarter surged 1,200 percent to $20.83 million from $1.60 million in the previous year period.
Operating loss for the quarter was $58.47 million, compared with an operating loss of $23.53 million in the previous year period.
"JCAR017, a key product candidate of our CD19 platform, has shown encouraging preliminary efficacy and safety results in NHL and pediatric ALL. At the upcoming American Society of Hematology meeting, additional data from our Phase I trial for JCAR017 in NHL patients will be presented," said Hans Bishop, Juno's President and chief executive officer. "Progress with CAR T therapy continues as we strive to bring these innovative product candidates to patients battling cancer. We look forward to the upcoming presentations at ASH, including 11 total presentations from a number of ongoing and completed studies."
Working capital drops significantlyJuno Therapeutics has witnessed a decline in the working capital over the last year. It stood at $711.74 million as at Sep. 30, 2016, down 30.46 percent or $311.80 million from $1,023.54 million on Sep. 30, 2015. Current ratio was at 6.35 as on Sep. 30, 2016, down from 7.85 on Sep. 30, 2015.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
